These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 31751318)

  • 1. Mitochondrial arginase-2 is a cell‑autonomous regulator of CD8+ T cell function and antitumor efficacy.
    Martí i Líndez AA; Dunand-Sauthier I; Conti M; Gobet F; Núñez N; Hannich JT; Riezman H; Geiger R; Piersigilli A; Hahn K; Lemeille S; Becher B; De Smedt T; Hugues S; Reith W
    JCI Insight; 2019 Nov; 4(24):. PubMed ID: 31751318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by
    Abu Eid R; Ahmad S; Lin Y; Webb M; Berrong Z; Shrimali R; Kumai T; Ananth S; Rodriguez PC; Celis E; Janik J; Mkrtichyan M; Khleif SN
    Cancer Res; 2017 Aug; 77(15):4135-4145. PubMed ID: 28615225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinatorial immunotherapy induces tumor-infiltrating CD8
    Van Braeckel-Budimir N; Dolina JS; Wei J; Wang X; Chen SH; Santiago P; Tu G; Micci L; Al-Khami AA; Pfister S; Ram S; Sundar P; Thomas G; Long H; Yang W; Potluri S; Salek-Ardakani S
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
    Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
    Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
    Zhang X; Niedermann G
    Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.
    Church SE; Jensen SM; Antony PA; Restifo NP; Fox BA
    Eur J Immunol; 2014 Jan; 44(1):69-79. PubMed ID: 24114780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NF-κB-inducing kinase maintains T cell metabolic fitness in antitumor immunity.
    Gu M; Zhou X; Sohn JH; Zhu L; Jie Z; Yang JY; Zheng X; Xie X; Yang J; Shi Y; Brightbill HD; Kim JB; Wang J; Cheng X; Sun SC
    Nat Immunol; 2021 Feb; 22(2):193-204. PubMed ID: 33398181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.
    Chen S; Lee LF; Fisher TS; Jessen B; Elliott M; Evering W; Logronio K; Tu GH; Tsaparikos K; Li X; Wang H; Ying C; Xiong M; VanArsdale T; Lin JC
    Cancer Immunol Res; 2015 Feb; 3(2):149-60. PubMed ID: 25387892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
    Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
    Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amino acids and RagD potentiate mTORC1 activation in CD8
    Zhang Y; Hu H; Liu W; Yan SM; Li Y; Tan L; Chen Y; Liu J; Peng Z; Yuan Y; Huang W; Yu F; He X; Li B; Zhang H
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expansion of Tumor-Infiltrating CD8
    Fernandez-Poma SM; Salas-Benito D; Lozano T; Casares N; Riezu-Boj JI; Mancheño U; Elizalde E; Alignani D; Zubeldia N; Otano I; Conde E; Sarobe P; Lasarte JJ; Hervas-Stubbs S
    Cancer Res; 2017 Jul; 77(13):3672-3684. PubMed ID: 28522749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment.
    Steggerda SM; Bennett MK; Chen J; Emberley E; Huang T; Janes JR; Li W; MacKinnon AL; Makkouk A; Marguier G; Murray PJ; Neou S; Pan A; Parlati F; Rodriguez MLM; Van de Velde LA; Wang T; Works M; Zhang J; Zhang W; Gross MI
    J Immunother Cancer; 2017 Dec; 5(1):101. PubMed ID: 29254508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of SHP-1 Expands the Repertoire of Antitumor T Cells Available to Respond to Immune Checkpoint Blockade.
    Snook JP; Soedel AJ; Ekiz HA; O'Connell RM; Williams MA
    Cancer Immunol Res; 2020 Apr; 8(4):506-517. PubMed ID: 32075800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repression of arginase-2 expression in dendritic cells by microRNA-155 is critical for promoting T cell proliferation.
    Dunand-Sauthier I; Irla M; Carnesecchi S; Seguín-Estévez Q; Vejnar CE; Zdobnov EM; Santiago-Raber ML; Reith W
    J Immunol; 2014 Aug; 193(4):1690-700. PubMed ID: 25009204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor.
    Bai X; Wang X; Ma G; Song J; Liu X; Wu X; Zhao Y; Liu X; Liu Z; Zhang W; Zhao X; Zheng Z; Jing J; Shi H
    Front Immunol; 2021; 12():793831. PubMed ID: 34987517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
    Hu HM; Winter H; Urba WJ; Fox BA
    J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P2X7 Receptor Activity Limits Accumulation of T Cells within Tumors.
    Romagnani A; Rottoli E; Mazza EMC; Rezzonico-Jost T; De Ponte Conti B; Proietti M; Perotti M; Civanelli E; Perruzza L; Catapano AL; Baragetti A; Tenedini E; Tagliafico E; Falzoni S; Di Virgilio F; Norata GD; Bicciato S; Grassi F
    Cancer Res; 2020 Sep; 80(18):3906-3919. PubMed ID: 32699136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arginase Therapy Combines Effectively with Immune Checkpoint Blockade or Agonist Anti-OX40 Immunotherapy to Control Tumor Growth.
    Badeaux MD; Rolig AS; Agnello G; Enzler D; Kasiewicz MJ; Priddy L; Wiggins JF; Muir A; Sullivan MR; Van Cleef J; Daige C; Vander Heiden MG; Rajamanickam V; Wooldridge JE; Redmond WL; Rowlinson SW
    Cancer Immunol Res; 2021 Apr; 9(4):415-429. PubMed ID: 33500272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
    Winter H; Hu HM; McClain K; Urba WJ; Fox BA
    J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell-Mediated Tumor Immunity.
    Büll C; Boltje TJ; Balneger N; Weischer SM; Wassink M; van Gemst JJ; Bloemendal VR; Boon L; van der Vlag J; Heise T; den Brok MH; Adema GJ
    Cancer Res; 2018 Jul; 78(13):3574-3588. PubMed ID: 29703719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.